FIGURE LEGENDS (Supplemented figures)

Figures s1-s5. Pre- and post-vaccination concentrations (mg/L) of C2-deficient (C2D) persons and controls (n=51) are depicted in a Log10 (x) to Log10 (y) scale; (A) pneumococci type 6B, (B) pneumococci type 7F, (C) pneumococci type 23F and (D) H. influenzae type b. Twenty-five C2D persons were vaccinated with the 23-valent pneumococcal vaccine (Pneumo 23®) and 21 were included after vaccination with H. influenzae type b conjugate vaccine (ActHIB®). Mean trend lines were added to facilitate interpretation of the data: C2D dotted lines and controls broken lines. The non-broken lines represent a 1:1 response. For both C2D persons and controls, the post-vaccination geometric mean concentration (GMC) with range is presented. Closed symbols indicate C2D persons. Statistical results concerning antibody responses are shown for the C2D persons and controls (Wilcoxon signed rank test). Comparisons between C2D persons and controls in fold increase (FI) and post-vaccination concentrations are also included (Mann-Whitney U test).
C2D GMC 5.4 mg/L, range 0.01-179.0 mg/L, $p=0.0006$.
 Controls GMC 4.7 mg/L, range 0.07-120.0 mg/L, $p<0.0001$.
 C2D compared to controls; FI $p=0.005$, Post-vaccination concentration $p=0.5$.

C2D GMC 3.0 mg/L, range 0.4-65.0 mg/L, $p=0.004$.
 Controls GMC 7.7 mg/L, range 0.1-80.0 mg/L, $p<0.0001$.
 C2D compared to controls; FI $p<0.0001$. Post-vaccination concentration $p=0.0006$.

C2D GMC 3.3 mg/L, range 0.2-36.0 mg/L, $p<0.0001$.
 Controls GMC 3.5 mg/L, range 0.04-72.0 mg/L, $p<0.0001$.
 C2D compared to controls; FI $p=0.3$. Post-vaccination concentration $p=0.5$.

C2D GMC 9.4 mg/L, range 0.9-48.0 mg/L, $p<0.0001$.
 Controls GMC 35.2 mg/L, range 1.5-77.0 mg/L, $p<0.0001$.
 C2D compared to controls; FI $p=0.0008$. Post-vaccination concentration $p<0.0001$.

**Figure s1.**
A

Pneumococci 6B, IgA

C2D GMC 0.7 mg/L, range 0.07-9.8 mg/L, p < 0.0001.

Controls GMC 0.6 mg/L, range 0.01-13.0 mg/L, p < 0.0001.

C2D compared to controls; FI p = 0.8. Post-vaccination concentration p = 0.9.

B

Pneumococci 7F, IgA

C2D GMC 0.3 mg/L, range 0.02-2.5 mg/L, p < 0.0001.

Controls GMC 0.9 mg/L, range 0.1-5.4 mg/L, p < 0.0001.

C2D compared to controls; FI p < 0.0001. Post-vaccination concentration p < 0.0001.

C

Pneumococci 23F, IgA

C2D GMC 0.4 mg/L, range 0.01-3.4 mg/L, p = 0.002.

Controls GMC 0.2 mg/L, range 0.01-3.4 mg/L, p < 0.0001.

C2D compared to controls; FI p = 0.2. Post-vaccination concentration p = 0.05.

D

Hib, IgA

C2D GMC 0.5 mg/L, range 0.01-13.0 mg/L, p = 0.0004.

Controls GMC 7.1 mg/L, range 0.2-52.0 mg/L, p < 0.0001.

C2D compared to controls; FI p < 0.0001. Post-vaccination concentration p < 0.0001.

Figure s2.
A

Pneumococci 6B, IgM

C2D GMC 3.4 mg/L, range 0.02-29.0 mg/L, \( p < 0.0001 \).

Controls GMC 4.7 mg/L, range 0.2-67.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.01 \). Post-vaccination concentration \( p = 0.3 \).

B

Pneumococci 7F, IgM

C2D GMC 2.2 mg/L, range 0.03-8.6 mg/L, \( p < 0.0001 \).

Controls GMC 3.1 mg/L, range 0.2-26.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.0008 \). Post-vaccination concentration \( p = 0.5 \).

C

Pneumococci 23F, IgM

C2D GMC 0.9 mg/L, range 0.1-8.9 mg/L, \( p = 0.006 \).

Controls GMC 1.0 mg/L, range 0.07-30.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.01 \). Post-vaccination concentration \( p = 0.8 \).

D

Hib, IgM

C2D GMC 1.0 mg/L, range 0.01-340.0 mg/L, \( p < 0.0001 \).

Controls GMC 4.9 mg/L, range 0.1-77.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p < 0.0001 \). Post-vaccination concentration \( p = 0.01 \).

Figure s3.
C2D GMC 0.2 mg/L, range 0.03-3.8 mg/L, \( p = 0.0001 \).

Controls GMC 0.2 mg/L, range 0.01-21.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.005 \). Post-vaccination concentration \( p = 0.1 \).

C2D GMC 0.1 mg/L, range 0.02-0.9 mg/L, \( p = 0.004 \).

Controls GMC 0.3 mg/L, range 0.01-6.7 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p < 0.0001 \). Post-vaccination concentration \( p = 0.0001 \).

C2D GMC 0.2 mg/L, range 0.02-2.5 mg/L, \( p = 0.0006 \).

Controls GMC 0.2 mg/L, range 0.01-5.2 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.06 \). Post-vaccination concentration \( p = 0.7 \).

C2D GMC 1.0 mg/L, range 0.02-60.0 mg/L, \( p < 0.0001 \).

Controls GMC 17.2 mg/L, range 0.3-112.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p < 0.0001 \). Post-vaccination concentration \( p < 0.0001 \).

**Figure s4.**
A

Pneumococci 6B, IgG2

C2D GMC 4.5 mg/L, range 0.05-71.0 mg/L, \( p = 0.0003 \).

Controls GMC 4.0 mg/L, range 0.01-125.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.003 \). Post-vaccination concentration \( p = 0.9 \).

B

Pneumococci 7F, IgG2

C2D GMC 3.8 mg/L, range 0.2-65.0 mg/L, \( p < 0.0001 \).

Controls GMC 5.8 mg/L, range 0.01-46.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p < 0.0001 \). Post-vaccination concentration \( p = 0.04 \).

C

Pneumococci 23F, IgG2

C2D GMC 2.9 mg/L, range 0.1-36.0 mg/L, \( p < 0.0001 \).

Controls GMC 3.1 mg/L, range 0.01-68.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p = 0.1 \). Post-vaccination concentration \( p = 0.7 \).

D

Hib, IgG2

C2D GMC 5.9 mg/L, range 0.3-56.0 mg/L, \( p < 0.0001 \).

Controls GMC 14.7 mg/L, range 0.01-618.0 mg/L, \( p < 0.0001 \).

C2D compared to controls; FI \( p < 0.0001 \). Post-vaccination concentration \( p = 0.02 \).

Figure s5.